Literature DB >> 30224343

The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival.

Saskia J Santegoets1, Vanessa J van Ham1, Ilina Ehsan1, Pornpimol Charoentong2, Chantal L Duurland1, Vincent van Unen3, Thomas Höllt4,5, Lilly-Ann van der Velden6, Sylvia L van Egmond6, Kim E Kortekaas7, Peggy J de Vos van Steenwijk7, Mariëtte I E van Poelgeest7, Marij J P Welters1, Sjoerd H van der Burg8.   

Abstract

PURPOSE: The tumor immune microenvironment determines clinical outcome. Whether the original tissue in which a primary tumor develops influences this microenvironment is not well understood. EXPERIMENTAL
DESIGN: We applied high-dimensional single-cell mass cytometry [Cytometry by Time-Of-Flight (CyTOF)] analysis and functional studies to analyze immune cell populations in human papillomavirus (HPV)-induced primary tumors of the cervix (cervical carcinoma) and oropharynx (oropharyngeal squamous cell carcinoma, OPSCC).
RESULTS: Despite the same etiology of these tumors, the composition and functionality of their lymphocytic infiltrate substantially differed. Cervical carcinoma displayed a 3-fold lower CD4:CD8 ratio and contained more activated CD8+CD103+CD161+ effector T cells and less CD4+CD161+ effector memory T cells than OPSCC. CD161+ effector cells produced the highest cytokine levels among tumor-specific T cells. Differences in CD4+ T-cell infiltration between cervical carcinoma and OPSCC were reflected in the detection rate of intratumoral HPV-specific CD4+ T cells and in their impact on OPSCC and cervical carcinoma survival. The peripheral blood mononuclear cell composition of these patients, however, was similar.
CONCLUSIONS: The tissue of origin significantly affects the overall shape of the immune infiltrate in primary tumors. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30224343     DOI: 10.1158/1078-0432.CCR-18-1749

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Tissue-Specific Gene Expression during Productive Human Papillomavirus 16 Infection of Cervical, Foreskin, and Tonsil Epithelium.

Authors:  Sreejata Chatterjee; Sa Do Kang; Samina Alam; Anna C Salzberg; Janice Milici; Sjoerd H van der Burg; Willard Freeman; Craig Meyers
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

Review 2.  Tumor Immunity and Immunotherapy for HPV-Related Cancers.

Authors:  Achraf A Shamseddine; Bharat Burman; Nancy Y Lee; Dmitriy Zamarin; Nadeem Riaz
Journal:  Cancer Discov       Date:  2021-05-14       Impact factor: 39.397

3.  Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses.

Authors:  S J Santegoets; C L Duurland; E S Jordanova; J J van Ham; I Ehsan; S L van Egmond; M J P Welters; S H van der Burg
Journal:  J Immunother Cancer       Date:  2019-01-18       Impact factor: 13.751

Review 4.  The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer.

Authors:  Hao-Fan Wang; Sha-Sha Wang; Ya-Jie Tang; Yu Chen; Min Zheng; Ya-Ling Tang; Xin-Hua Liang
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

5.  High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity.

Authors:  Vincent van Unen; Marieke E Ijsselsteijn; Tamim Abdelaal; Frits Koning; Noel F C C de Miranda; Natasja L de Vries; Ruud van der Breggen; Arantza Farina Sarasqueta; Ahmed Mahfouz; Koen C M J Peeters; Thomas Höllt; Boudewijn P F Lelieveldt
Journal:  Gut       Date:  2019-07-03       Impact factor: 23.059

6.  High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Authors:  Kim E Kortekaas; Saskia J Santegoets; Ziena Abdulrahman; Vanessa J van Ham; Marij van der Tol; Ilina Ehsan; Helena C van Doorn; Tjalling Bosse; Mariëtte I E van Poelgeest; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2019-09-03       Impact factor: 13.751

7.  High-dimensional single-cell proteomics analysis reveals the landscape of immune cells and stem-like cells in renal tumors.

Authors:  Zhijian Li; Jiaxin Hu; Zhao Qin; Yuting Tao; Zhiyong Lai; Qiuyan Wang; Tianyu Li
Journal:  J Clin Lab Anal       Date:  2019-12-19       Impact factor: 2.352

8.  Bilateral murine tumor models for characterizing the response to immune checkpoint blockade.

Authors:  Rachael M Zemek; Vanessa S Fear; Cath Forbes; Emma de Jong; Thomas H Casey; Louis Boon; Timo Lassmann; Anthony Bosco; Michael J Millward; Anna K Nowak; Richard A Lake; W Joost Lesterhuis
Journal:  Nat Protoc       Date:  2020-04-01       Impact factor: 13.491

9.  Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer.

Authors:  Anders Handrup Kverneland; Magnus Pedersen; Marie Christine Wulff Westergaard; Morten Nielsen; Troels Holz Borch; Lars Rønn Olsen; Gitte Aasbjerg; Saskia J Santegoets; Sjoerd H van der Burg; Katy Milne; Brad H Nelson; Özcan Met; Marco Donia; Inge Marie Svane
Journal:  Oncotarget       Date:  2020-06-02

10.  Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Authors:  Aurelie Hanoteau; Jared M Newton; Rosemarie Krupar; Chen Huang; Hsuan-Chen Liu; Angelina Gaspero; Robyn D Gartrell; Yvonne M Saenger; Thomas D Hart; Saskia J Santegoets; Damya Laoui; Chad Spanos; Falguni Parikh; Padmini Jayaraman; Bing Zhang; Sjoerd H Van der Burg; Jo A Van Ginderachter; Cornelis J M Melief; Andrew G Sikora
Journal:  J Immunother Cancer       Date:  2019-01-15       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.